Skip to main content

Lipid Nano Spheres (LNSs) for Enhanced Oral Bioavailability of Amphotericin B: Development and Characterization

Buy Article:

$113.00 plus tax (Refund Policy)

Abstract:

Amphotericin B is the gold standard for the treatment of systemic fungal infections and visceral leishmaniasis. Amphotericin B is not absorbed orally because of its poor aqueous solubility. Amphotericin B loaded Lipid Nano Spheres were prepared to improve its absorption from gastrointestinal tract. Lipid Nano Spheres (LNSs) of mono and triglycerides were prepared in different drug lipid ratios by melt dispersion technique. The influence of process variables like, type and amount of lipids, stirring speed and time were studied. The optimized LNSs were characterized for shape, size and size distribution and entrapment efficiency. The In vitro drug release profile of the LNSs showed approximately 40–50% release in 8 hours. In vivo efficacy was determined in healthy albino rats. After oral administration of the LNSs (33 mg/Kg body wt), the bioavailability was increased by approximately 40 times. The mechanism of enhanced absorption of LNSs is not clear, the possible mode may be the lymphatic uptake of the LNSs by intestinal peyer's patches.

Keywords: AMPHOTERICIN B; LIPID NANO SPHERES; ORAL BIOAVAILABILITY

Document Type: Research Article

DOI: https://doi.org/10.1166/jbn.2007.029

Publication date: 2007-09-01

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more